TEGA THERAPEUTICS INC
- SAN DIEGO, CA 92121-1122
- tegatherapeutics.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 11, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
TEGA THERAPEUTICS INC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About TEGA THERAPEUTICS INC
- Headquarters
- SAN DIEGO, CA 92121-1122
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIC1LJLCS3PM51
- CAGE6W1N1
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 11 awards
- Total awarded
- $4,034,298
- By phase
- SBIR Phase I: 9
- SBIR Phase II: 1
- STTR Phase I: 1
- By agency
- Department of Health and Human Services: 8
- National Science Foundation: 3
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2025: 1
- 2024: 1
- 2023: 1
- 2022: 1
- 2021: 1
- 2020: 1
- 2019: 2
- 2018: 1
- 2016: 1
- 2015: 1
Awards (most recent first)
Title: New Clinical Biomarkers for GM1 Gamgliosidosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $500,000
Aug 5, 2025 – Jul 31, 2026
Solicitation PA24-245 (2024) · Topic 102
Testing Novel Advancements to Recombinant Heparin Production
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $355,222
Feb 1, 2024 – Jan 31, 2025
Solicitation PA22-176 (2022) · Topic NHLBI
Title: Development and Validation of Therapy for GM1 Gangliosidosis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $461,701
Sep 15, 2023 – Aug 31, 2024
Solicitation PA22-176 (2022) · Topic 107
Developing non-anticoagulant recombinant heparin for treating the COPD Pathogenic Triad
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $321,866
Feb 5, 2022 – Jan 31, 2023
Solicitation PA20-260 (2020) · Topic NHLBI
SBIR Phase II: Development of Bioengineered Anticoagulant Heparin from a Non-Animal Source
SBIR Phase II · National Science Foundation · 2021 · $999,948
Dec 15, 2020 – Nov 30, 2022
Solicitation year 2020 · Topic BT
Title: Intracerebroventricular sulfamidase delivery to the Brain
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $258,169
Apr 15, 2020 – Mar 31, 2021
Solicitation PA19-272 (2019) · Topic NINDS
Intracerebroventricular alpha-N-acetylglucosaminidase Delivery to the Brain
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $225,254
Aug 1, 2019 – Jul 31, 2020
Solicitation PA18-574 (2018) · Topic NINDS
SBIR Phase I: Bioengineered Recombinant Anticoagulant Heparin
SBIR Phase I · National Science Foundation · 2019 · $225,000
Feb 1, 2019 – Jan 31, 2020
Solicitation year 2018 · Topic BT
Intracerebroventricular Iduronidase Delivery to the Brain
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $225,000
Aug 1, 2018 – Jul 31, 2019
Solicitation PA17-302 (2017) · Topic NINDS
STTR Phase I: Biomanufacture of Novel Heparan Sulfate Glycosaminoglycans
STTR Phase I · National Science Foundation · 2016 · $225,000
Jul 1, 2016 – Jun 30, 2017
Solicitation year 2015 · Topic BT · Research partner: State University of New York
Intranasal Sulfamidase Delivery to the Brain
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $237,138
Sep 15, 2015 – Sep 14, 2016
Solicitation PA14-072 (2015) · Topic 105
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 622110General Medical and Surgical HospitalsPrimarySmall business under this code’s size standard
SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 11, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with TEGA THERAPEUTICS INC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.